Amgen Inc.’s Stock Price Drops to $299.48, Marking a 3.79% Decrease: Time to Buy or Bail?

Amgen Inc. (AMGN)

299.48 USD -11.81 (-3.79%) Volume: 4.72M

Amgen Inc.’s stock price stands at 299.48 USD, witnessing a decline of -3.79% this trading session, with a substantial trading volume of 4.72M. Despite the daily downturn, its year-to-date performance shows a positive trend with +3.98% growth, reflecting the stock’s resilience and potential.

Latest developments on Amgen Inc.

Amgen Inc‘s stock price is seeing significant movement today, driven by a combination of factors. Investors are flocking to Amgen, excited by the prospect of the next big obesity drug payout, particularly with the promising outlook for MariTide. The company’s strategic SWOT insight reveals a robust position as it prepares for a Phase 3 trial of Tavneos in children with AAV. Furthermore, Amgen’s commitment to tackling obesity through drug development has been noticed by StockWatch. However, recent news of SVP Nancy A. Grygiel selling 2117 shares has stirred the pot. Despite this, the stock soared nearly 12% higher today, with analysts setting the price target at $297.40, prompting questions on whether Amgen’s value is priced right.

Amgen Inc. on Smartkarma

Analysts at Baptista Research have been closely monitoring Amgen Inc‘s performance, with a bullish outlook on the company’s future. In their report titled “Amgen Inc: An Analysis Of The Pipeline Progress and Development! – Major Drivers,” they highlighted the strategic moves and positive outcomes from Amgen’s Fourth Quarter 2023 Financial Results Conference Call. The acquisition of Horizon Therapeutics and record annual sales for 18 of Amgen’s medicines have contributed to the company’s growth. Baptista Research aims to evaluate the various factors influencing Amgen’s stock price in the near future and conduct an independent valuation using a Discounted Cash Flow methodology.

In another report by Baptista Research titled “Amgen Inc.: Expansion Of Oncology Research & Other Major Drivers,” analysts noted a mixed set of results for the previous quarter, with revenues falling below expectations but managed earnings beating estimates. Despite this, Amgen achieved significant quarterly sales for key brands and saw growth across various portfolios, including general medicine, inflammation, and hematology/oncology. Notably, Prolia reported a 14% year-over-year sales increase in the bone health segment, driven by volume growth and higher selling prices. The analysts at Baptista Research continue to track Amgen Inc‘s performance and provide insights into the company’s growth potential.

A look at Amgen Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Amgen Inc. is an independent biotechnology company that focuses on developing medicines for serious diseases. Utilizing the Smartkarma Smart Scores, Amgen Inc. received a high score for Dividend and Momentum, indicating a positive outlook in terms of providing dividends to investors and having strong market momentum. However, the company scored lower in Value and Resilience, suggesting potential challenges in terms of valuation and resilience in the face of market fluctuations. With a moderate score for Growth, Amgen Inc. may see steady but not rapid growth in the long term.

Based on the Smartkarma Smart Scores, Amgen Inc. shows promise in terms of dividends and market momentum. However, there are areas such as value and resilience where the company may face challenges. With a focus on developing innovative medicines based on scientific advancements, Amgen Inc. is positioned to continue its work in providing treatments for serious illnesses. Investors may want to consider these factors when evaluating the long-term outlook for Amgen Inc.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma